Xylem Inc.XYLTOP PICKJan 11, 2017Stock price when the opinion was issued
As of Jun 05, 2026. Market Open.
Treats, transports, and tests water (drinking and wastewater). Water is a scarce resource; 70% of the earth is water, but only about 2% is drinkable. Aging infrastructure in developed countries needs to be refurbished. Lots of industries require water. One of the few pure-play, publicly traded water companies, and so it trades at a premium.
International, with 50% of earnings coming from the US. Going through an operating margin improvement program, to refine focus on customers and products that are most lucrative. Yield is 1.24%.
Dominant in water sector. One of the few publicly listed pure plays, so valuation tends to be elevated. Treat, transport, and test water. Clients are utility companies and industrials. Water is a scarce resource. Likes the new acquisition, accretive to earnings in the long run, will expand presence in the space.
Fundamentals remain attractive. She likes the water industry and this is a rare pure-water company. Benefits from ESG fund flows, so the share price ran up to overvalue. It's now more attractive. The semi chip shortage is impacting their business, so they can't fulfill all their orders. Will take time to fill these orders this year. She's long owned this. Definitely hold this. She is slowing adding to her holdings.
This was a spin out from ITT Corp in 2011. They make water equipment and sources to the water industry. Their products encompass anywhere from water transportation (pumps, valves, controls), treatment and testing. Their end markets include municipalities, utilities, industrial clients, building services, commercial clients, and even the agricultural industry. 70% of the globe is made up of water, but only 1% is actually drinkable or potable. There is the issue of emerging markets, where they are still building out their water infrastructure. In the developed markets, there is the problem of aging infrastructure which needs replacement. Dividend yield of 1.26%. (Analysts’ price target is $53.58.)